Details:

Alternative Title:
Clin Infect Dis
Publisher's site:
http://dx.doi.org/10.1093/cid/ciz956
Personal Author:
Tsertsvadze, Tengiz ; Gamkrelidze, Amiran ; Chkhartishvili, Nikoloz ; Abutidze, Akaki ; Sharvadze, Lali ; ... More +
Tsertsvadze, Tengiz ; Gamkrelidze, Amiran ; Chkhartishvili, Nikoloz ; Abutidze, Akaki ; Sharvadze, Lali ; Kerashvili, Vakhtang ; Butsashvili, Maia ; Metreveli, David ; Gvinjilia, Lia ; Shadaker, Shaun ; Nasrullah, Muazzam ; Adamia, Ekaterine ; Zeuzem, Stefan ; Afdhal, Nezam ; Arora, Sanjeev ; Thornton, Karla ; Skaggs, Beth ; Kuchuloria, Tinatin ; Lagvilava, Maia ; Sergeenko, David ; Averhoff, Francisco Less -
Description:
Background:

In April 2015, in collaboration with the US Centers for Disease Control and Prevention and Gilead Sciences, the country of Georgia embarked on the world’s first hepatitis C elimination program. We aimed to assess progress toward elimination targets 3 years after the start of the elimination program.

Methods:

We constructed a hepatitis C virus (HCV) care cascade for adults in Georgia, based on the estimated 150 000 persons aged ≥18 years with active HCV infection. All patients who were screened or entered the treatment program during April 2015–March 2018 were included in the analysis. Data on the number of persons screened for HCV were extracted from the national HCV screening database. For the treatment component, we utilized data from the Georgia National HCV treatment program database. Available treatment options included sofosbuvir and ledipasvir/sofosbuvir–based regimens.

Results:

Since April 2015, a cumulative 974 817 adults were screened for HCV antibodies; 86 624 persons tested positive, of whom 61 925 underwent HCV confirmatory testing. Among the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 45 334 (30.2%) initiated treatment with direct-acting antivirals, and 29 090 (19.4%) achieved a sustained virologic response (SVR). Overall, 37 256 persons were eligible for SVR assessment; of these, only 29 620 (79.5%) returned for evaluation. The SVR rate was 98.2% (29 090/29 620) in the per-protocol analysis and 78.1% (29 090/37 256) in the intent-to-treat analysis.

Conclusions:

Georgia has made substantial progress in the path toward eliminating hepatitis C. Scaling up of testing and diagnosis, along with effective linkage to treatment services, is needed to achieve the goal of elimination.


Subject:
[+]
Adolescent
Adult
Antiviral Agents
Article
Cascade
Elimination
Georgia
Georgia (Republic)
HCV
Hepacivirus
Hepatitis C
Hepatitis C, Chronic
Humans
Sofosbuvir
Sustained Virologic Response

Source:
Clin Infect Dis. 71(5):1263-1268
Pubmed ID:
31563938
Pubmed Central ID:
PMC7484896
Document Type:
Journal Article
Funding:
CC999999/ImCDC/Intramural CDC HHSUnited States/
Place as Subject:
Georgia
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:7ffc71da8b9b07ac32cd262ea91064296706e1c6724ffd8a659a2aed3de54409
File Type:

Supporting Files

• 	nihms-1624608-f0001.gif	gif
  	nihms-1624608-f0001.jpg	jpeg
  	nihms-1624608-f0002.gif	gif
  	nihms-1624608-f0002.jpg	jpeg
  	nihms-1624608.nxml	xml

More +